The primary therapeutic role of БИМОПТИК РОМФАРМ is centered on controlling the internal pressure dynamics of the eye to assist with maintaining functional stability. The medication addresses a core pathological risk factor rather than subjective symptoms.

Management of Primary Open-Angle Glaucoma and Ocular Hypertension

This ophthalmic solution is commonly used to help with conditions defined by chronically elevated eye pressure, specifically Primary Open-Angle Glaucoma and Ocular Hypertension. The medicine is used for the reduction of this elevated pressure in adults. The therapeutic approach is relevant for easing the symptoms linked to organ-specific functional stress by stabilizing this internal pressure.

Sustained Control of Chronically Elevated Eye Pressure

The key benefit provided to the patient is generally the support for a sustained and stable reduction in the chronically elevated IOP. By maintaining the pressure within a suitable range, the medication helps to manage the stress on the optic nerve, which assists with maintaining functional stability and supports general well-being.

---

Quick Fact: Relief for Pathological Pressure	Category	Description
Primary Indication	Ocular Hypertension and Primary Open-Angle Glaucoma
Symptom Domain	Pathological Elevation of Intraocular Pressure (IOP)
Key Benefit	Supports the preservation of visual function by managing IOP
Clinical Context	Long-term therapeutic stability and continuous risk management

Regulatory References

1. European Medicines Agency (EMA) product information for Bimatoprost

Eligibility for БИМОПТИК РОМФАРМ

БИМОПТИК РОМФАРМ (Bimatoprost/Timolol) is generally intended for adult patients (18 years and older) who do not have any contraindications.

Absolute Non-Eligibility (Contraindications)

The medicine must not be used by patients with:

• Hypersensitivity (allergy) to bimatoprost, timolol, beta-blockers, or any excipients.
• Respiratory Conditions: Bronchial asthma (or a history of it) or severe Chronic Obstructive Pulmonary Disease (COPD).
• Cardiac Conditions: Sinus bradycardia, severe heart block (second or third-degree, uncontrolled by pacemaker), overt cardiac failure, or cardiogenic shock.

Restricted or Conditional Use

Use requires caution and a critical assessment by a healthcare professional in patients with:

• Cardiovascular Issues: History of coronary heart disease, heart failure (other than overt), or hypotension.
• Endocrine/Metabolic Disorders: Labile diabetes or hyperthyroidism (as symptoms may be masked).
• Organ Impairment: Known liver or kidney problems (due to limited study data).
• Ocular Risk Factors: Active intraocular inflammation or risk factors for macular edema.

Age and Reproductive Status

• Pediatric Population: Use is not recommended in children and adolescents under 18 years of age (safety and efficacy are not established).
• Pregnancy and Breastfeeding: The medication should not be used during pregnancy unless clearly necessary. It must not be used by breastfeeding women.

Interactions with other medicines and products

The official interaction profile for this combination product addresses potential risks primarily associated with the timolol component, a beta-blocker, and the bimatoprost component, a prostaglandin analogue.

Potential Interaction Categories

Interacting Product Category	Nature of Interaction
Other Ophthalmic Beta-Blockers	Concurrent use is not recommended due to potential additive effects.
Other Prostaglandin Analogues	Concomitant use may result in a reduced intraocular pressure-lowering effect, requiring monitoring.
Cardiovascular/Autonomic Agents	Co-administration with oral calcium channel blockers, guanethidine, other systemic beta-adrenergic blocking agents, parasympathomimetics, and anti-arrhythmics (such as amiodarone) may cause additive effects like hypotension and marked bradycardia.
CYP2D6 Inhibitors	Specific inhibitors, including quinidine, fluoxetine, and paroxetine, can potentiate systemic beta-blockade, leading to effects like decreased heart rate and depression.

Procedural and Timing Requirements

If the use of more than one topical ophthalmic medicinal product is required, each product should be administered with a minimum time interval of five minutes between applications. The surgical team, particularly the anaesthesiologist, should be informed that the patient is receiving a beta-blocking agent prior to general anaesthesia, as these agents may affect the body’s response to beta-agonist effects during surgery. Systemic exposure to bimatoprost is minimal following ocular administration, and clinically significant drug-drug interactions involving this component are not anticipated.

How БИМОПТИК РОМФАРМ Works

БИМОПТИК РОМФАРМ's mechanism relies entirely on the precise, localized action of Bimatoprost within the eye's fluid drainage structures. The compound functions by selectively modulating the biological pathways that regulate the outflow of aqueous humor, thereby reducing the internal fluid resistance.

---

️ Molecular Agonism at Prostamide Receptors

This domain covers the initial trigger where the drug's active molecule binds to specific prostamide receptors on cells within the eye's drainage tissue. This targeted receptor activation initiates an intracellular signal cascade that begins the process of tissue change.

---

Tissue Remodeling and Outflow Pathway Modulation

This core mechanism involves the drug-induced structural remodeling of the tissue surrounding the fluid pathways. The molecular signal cascade increases the expression of Matrix Metalloproteinases (MMPs), which act as enzymes to physically loosen the Extracellular Matrix (ECM). This action reduces resistance and increases the rate of fluid outflow via the uveoscleral pathway.

---

Resulting Physiological Pressure Reduction

The modulation of tissue structure and enhanced drainage capacity results in the physiological effect of a reduction in the eye's internal pressure. This mechanism contributes to the regulation of local fluid dynamics by increasing the capacity for fluid outflow.

Official Administration Guidelines: How to use БИМОПТИК РОМФАРМ

These instructions describe the official use protocol for this ophthalmic solution containing bimatoprost.

Administration Details

Attribute	Official Instruction
Route	Topical Ocular Instillation (into the affected eye(s))
Dosing Rule	One drop in the affected eye(s) once daily. Administration must not exceed once daily to maintain efficacy.
Timing	Recommended to be administered in the evening.
Age Group	For use in adults (including the elderly). Use in children and adolescents (age 0-18 years) is not recommended as safety and efficacy have not been established.
Missed Dose	If a dose is missed, continue with the next scheduled dose. Do not use a double dose to compensate for a forgotten one.

Required Procedural Steps

1. Preparation and Hygiene: Wash hands thoroughly before application. Avoid touching the eye, surrounding structures, or any other surface with the tip of the container to prevent contamination and potential bacterial keratitis.
2. Contact Lenses: Soft contact lenses must be removed prior to instillation and may be reinserted 15 minutes following the administration.
3. Co-Administration: If using more than one topical ophthalmic medicine, administer the drops at least five (5) minutes apart.
4. Post-Instillation: After placing the drop, apply gentle pressure with a finger to the corner of the closed eye (nasolacrimal occlusion) for two minutes to reduce systemic absorption.
5. Excess Solution: Any excess solution on the eyelid or surrounding skin should be blotted away with a clean tissue, as the solution can potentially cause hair growth or darkening of the skin if repeated contact occurs.

This strictly defined procedure ensures the intended therapeutic effect is achieved while adhering to established standards for ophthalmic administration.

Research Evidence / Overview of Studies for БИМОПТИК РОМФАРМ

This section provides an overview of the types of official research that have explored the use of the active ingredient, Bimatoprost, without offering any clinical advice or interpretation of treatment outcomes. Findings describe group patterns and reflect the specific conditions under which the studies were conducted.

---

Evidence Base for Primary Open-Angle Glaucoma

Research examining the active ingredient was studied for Primary Open-Angle Glaucoma (POAG), a condition where research examined outcomes related to chronically elevated internal eye pressure. The evidence base primarily consists of Randomized Controlled Trials (RCTs), which are controlled studies where participants are assigned to different groups, as well as Systematic Reviews that combine data from multiple RCTs.

These studies focused on measuring the change in Intraocular Pressure (IOP) from baseline, which served as a primary measurement of interest. Researchers also explored the consistency of this IOP measurement over defined time intervals. Findings describe patterns observed in the studies where patients' pressure measurements were tracked against those using pre-specified comparator agents.

While the IOP measurements were documented in the short term, research also included observation of IOP measurement patterns over longer periods. Long-term extension studies were conducted to monitor the IOP measurement consistency. However, research exploring secondary outcomes, such as how visual field metrics evolved in the observed populations, often involved observational settings, where follow-up durations were limited for some participants.

---

Evidence Base for Ocular Hypertension

The evidence base for Ocular Hypertension (OHT) is founded on controlled trials. Research examined how IOP evolved in adult patients with this condition, comparing measurements against those of active comparator agents or inactive solutions.

Studies monitored the IOP measurement to see if patterns related to pressure shift were observed. Findings indicate the stability of the pressure measurements over the course of the study periods. The research helps contextualize how patients' pressure dynamics were tracked during periods of temporary physiological imbalance in the eye.

Research explored the relationship between observed IOP measurements and progression metrics. However, research often uses IOP change measurements as the primary measurement, and dedicated, lengthy studies to track long-term functional metrics are difficult to conduct and the evidence remains limited.

---

⏳ Long-Term Research and Durability of Measurements

The evidence landscape includes both short-term initial measurement trials, typically lasting three to six months, and long-term extension studies that monitored patient cohorts for up to four years. These longer studies were designed to assess whether the measured patterns of IOP change were sustained over multiple years of observation.

These studies monitored the IOP measurements to understand the persistence of the observed IOP patterns. Findings describe the stability of the measured pressure over these extended periods. It is important to note that as follow-up durations increase, research quality may vary due to the complexities of tracking patients for many years, meaning the long-term data certainty is not established under the same rigorous conditions as the initial short-term RCTs.

Key Studies & References European Medicines Agency (EMA) product information for Bimatoprost

Common questions about БИМОПТИК РОМФАРМ (FAQ)

Q: What are the common and serious side effects I should watch out for?

A: According to official product information, the most common adverse reaction (very common) is conjunctival hyperaemia, which is eye redness. Other common effects include ocular pruritus (eye itching) and headache. The official list includes uncommon but noteworthy effects like iris hyperpigmentation (a color change in the iris) that may be permanent. A complete list of documented effects is available within the official product labeling.

Q: How long will it take before I notice an improvement in my eye pressure measurements?

A: Clinical studies indicate that the pressure-lowering effect of the active ingredient may be measurable within about 4 hours following administration. The peak effect is typically observed at approximately 8 to 12 hours.

Q: What happens if the solution runs down my cheek or eyelid?

A: Regulatory warnings indicate that excess solution should be blotted away from the eyelid or surrounding skin. Repeated contact may potentially result in localized skin darkening and hair growth in those areas. Removing the excess solution helps to minimize this risk.

Q: Can I use БИМОПТИК РОМФАРМ if I wear soft contact lenses?

A: Official guidance states that soft contact lenses should be removed before the administration of the eye drops. The excipient (benzalkonium chloride) can be absorbed by soft lenses. Lenses may be reinserted 15 minutes following administration of the solution.

Q: How should I properly dispose of the used or expired eye drop bottle?

A: To prevent environmental harm, regulatory requirements state that unused medicine or waste material must not be thrown away via household waste or wastewater. The official documentation advises consulting a local pharmacist or waste disposal company to ensure disposal is carried out correctly according to local requirements.

Q: What are the early signs or symptoms of an allergic reaction to the drug?

A: While the official labeling lists hypersensitivity (an allergy) as an absolute reason not to use the drug, it does not specifically describe the early symptoms of an allergic reaction (such as rash or swelling). If signs of a severe or serious allergic reaction are suspected, immediate medical attention is necessary.

Q: Is there a recommended technique to ensure the eye drops go into my eye correctly?

A: Official procedural steps emphasize hygiene, avoiding contamination, and post-instillation care, such as using nasolacrimal occlusion (applying gentle pressure to the inner corner of the closed eye). While specific details regarding positioning the eye or head are not consistently outlined in regulatory documentation, the procedure includes steps intended to reduce systemic absorption.

How to Store and Dispose of БИМОПТИК РОМФАРМ

The storage and disposal of БИМОПТИК РОМФАРМ (Bimatoprost/Timolol) must adhere strictly to official regulatory conditions to maintain stability and prevent environmental harm.

---

Storage and Stability

Condition	Requirement
Maximum Temperature	Do not store above 25 °C.
Child Safety	Keep out of the sight and reach of children.
Multi-Dose Shelf Life	Discard 4 weeks (28 days) after first opening the bottle.
Single-Dose Shelf Life	Use contents immediately after opening the container.

Disposal Requirements

• Do not throw away any medicines via wastewater or household waste.
• Disposal of unused product or waste material must be in accordance with local requirements.
• Consult your pharmacist on how to properly dispose of the medicine you no longer use.